MYCN pro-to-oncogene (MYCN) suppresses TFPI2 and promotes tumor invasiveness, while TGFBI counteracts this by restoring TFPI2 expression in neuroblastoma [90]. The gene discussed is MYCN; the disease is neuroblastoma.